The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2023 | The potential of CELMoDs for the treatment of R/R multiple myeloma
Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, University College London Hospitals NHS Foundation Trust, London, UK, explores the potential of cereblon E3 ligase modulatory drugs (CELMoDs), such as iberdomide and mezigdomide, as an alternative to traditional immunomodulatory agents in the treatment of relapsed/refractory (R/R) multiple myeloma (MM). CELMoDs show activity in those patients who are refractory to both lenalidomide and pomalidomide, with mezigdomide demonstrating encouraging efficacy in higher-risk patients. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: GSK
Honoraria: GSK, Janssen, BMS, AbbVie, Roche
Research Funding: GSK
Current Employment: University College London Hospitals NHS Foundation Trust
